Granted Patent
B2
US 12,624,053 · App. 19/308,863 · Granted May 12, 2026
Ras inhibitors
Assignee:
Revolution Medicines, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
Claims (6)
1 . A compound selected from the group of compounds consisting of:
2 . The compound of claim 1 , wherein the compound has the structure:
3 . The compound of claim 1 , wherein the compound has the structure:
4 . The compound of claim 1 , wherein the compound has the structure:
5 . The compound of claim 1 , wherein the compound has the structure:
6 . The compound of claim 1 , wherein the compound has the structure:
Assignments (2)
SECURITY INTEREST
Recorded Jan 12, 2026
From: REVOLUTION MEDICINES, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT
Reel/Frame 073439/0027 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 7, 2026
From: LIU, YANG; CREGG, JAMES
To: REVOLUTION MEDICINES, INC.
Reel/Frame 073389/0441 →
Continuity (5)
Continuation
18516457
· Nov 21, 2023
Provisional Application
63184599
· May 5, 2021
References Cited (50)
US 9119853B2
· Moss et al.
· 2015
[cited by applicant]
US 20130344030A1
· Steadman et al.
· 2013
[cited by applicant]
US 20160083373A1
· Xu
· 2016
[cited by applicant]
US 20170190734A1
· Aciro et al.
· 2017
[cited by applicant]
US 20210130303A1
· Koltun
· 2021
[cited by examiner]
US 20210130326A1
· Aggen
· 2021
[cited by examiner]
US 20210130369A1
· Koltun
· 2021
[cited by examiner]
US 20230374035A1
· Koltun et al.
· 2023
[cited by applicant]
US 20250051306A1
· Aggen et al.
· 2025
[cited by applicant]
US 20250074923A1
· Knox et al.
· 2025
[cited by applicant]
US 20250129097A1
· Cregg et al.
· 2025
[cited by applicant]
US 20250145643A1
· Koltun et al.
· 2025
[cited by applicant]
US 20250154171A1
· Knox et al.
· 2025
[cited by applicant]
US 20250197423A1
· Koltun et al.
· 2025
[cited by applicant]
US 20250255964A1
· Cregg et al.
· 2025
[cited by applicant]
US 20250269037A1
· Burnett et al.
· 2025
[cited by applicant]
WO WO9807743A1
· 1998
[cited by applicant]
WO WO2012131371A1
· 2012
[cited by applicant]
WO WO2013185103A1
· 2013
[cited by applicant]
WO WO2018081592A2
· 2018
[cited by applicant]
WO WO2018091634A1
· 2018
[cited by applicant]
WO WO2022060583A1
· 2022
[cited by applicant]
WO WO2022060836A1
· 2022
[cited by applicant]
WO WO2022217053A1
· 2022
[cited by applicant]
WO WO2022235870A1
· 2022
[cited by applicant]
WO WO2023015559A1
· 2023
[cited by applicant]
WO WO2023025832A1
· 2023
[cited by applicant]
WO WO2023086341A1
· 2023
[cited by applicant]
WO WO2023208005A1
· 2023
[cited by applicant]
WO WO2023232776A1
· 2023
[cited by applicant]
WO WO2024008610A1
· 2024
[cited by applicant]
WO WO2024008834A1
· 2024
[cited by applicant]
WO WO2024067857A1
· 2024
[cited by applicant]
U.S. Appl. No. 19/388,266, Liu et al.
[cited by applicant]
Banteli et al., “A synthesis of the C1—N12 tripeptide fragment of sanglifehrin A,” Tetrahedron Letters. 40(11):2109-2112 (Mar. 12, 1999).
[cited by applicant]
Doak et al., “Cyclophilin Succumbs to a Macrocyclic Chameleon,” J Med Chem. 61(21):9469-9472 (Nov. 2018).
[cited by applicant]
Nakamura et al., “Asymmetric reduction of ketones by Geotrichum candidum in the presence of AmberliteTM XAD, a solid organic solvent,” J Chem Soc., Perkin Trans 1:3205-3211 (2000).
[cited by applicant]
PubChem CID 130196149, <https://pubchem.ncbi.nlm.nih.gov/compound/130196149>, retrieved on Apr. 1, 2020 (10 pages).
[cited by applicant]